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Abstarct:  
The present study was aimed to develop transdermal drug delivery of Oxybutynin to overcome the first pass 
metabolism and to reduce frequency of dosing compared to oral route. Matrix type of transdermal patches was 
developed by using polymers eudragit L100 and eudragit S100.Transdermal patches were prepared by employing 
solvent casting method. Propylene glycol and Tween80 were selected as permeation enhancer and plasticizer. Drug 
excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions. 
Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the 
formulations were evaluated for various physical parameters Physical appearance, Flatness, Weight variation, 
Thickness, Folding endurance, Drug content, Moisture uptake, Moisture content and Swelling study and all the 
results were found to be were found to be with in the pharmacopeial limits, invitro drug release studies by using 
dialysis membrane. Among all the 12 formulations F6 formulation which contain HPMC K4M 300mg and Eudragit 
L-100 60mg  had shown 94% cumulative drug release with in 12 hours. And compared to HPMC K15M, HPMC 
K4M showed better drug release profile. For F6 formulation release kinetics were plotted and the Regression 
coefficient value was found to be high for Korsmeyer-peppas release model i.e., 0.9892. The n value was found to be 
0.6203 which indicates the drug release pattern was found to be  non-Fickian diffusion. 
Key words: Oxybutynin, Matrix type, Transdermal patches. 
Corresponding author: 
Aduri Prakash Reddy, 
Department of Pharmaceutics, 
Teja college of pharmacy, 
Kodad (TS),508206. 
*E-mail: aduri.prakash14@gmail.com 
 
Please cite this article in press as Aduri Prakash Reddy et al, Formulation and Invitro Evaluation of Oxybutynin 
Transdermal Patch, Indo Am. J. P. Sci, 2017; 4[05]. 
 
 
 
 
QR code 
 
IAJPS 2017, 4 (05), 1398-1405                Aduri Prakash Reddy et al               ISSN 2349-7750 
 
w w w . i a j p s . c o m  
 
Page 1399 
INTRODUCTION: 
Transdermal therapeutic systems are defined as self-
contained discrete dosage forms which, when applied 
to the intact skin, deliver the drug(s), through the 
skin, at controlled rate to the systemic circulation 
(USP 25).Transdermal patch is a medicated adhesive 
pad that is designed to release the active ingredient at 
a constant rate over a period of several hours to days 
after application to the skin. It is also called skin 
patch. A transdermal patch uses a special membrane 
to control the rate at which the drug contained within 
the patch can pass through the skin and into the 
bloodstream.Often, this promotes healing to an 
injured area of the body. An advantage of a 
transdermal drug delivery route over other types of  
medication delivery such as oral, topical, intravenous, 
intramuscular, etc. Is that the patch provides a 
controlled release of the medication into the patient, 
usually through either a porous membrane covering a 
reservoir of medication or through body heat melting 
thin layers of medication embedded in the adhesive. 
The main disadvantage to transdermal delivery 
systems stems from the fact that the skin is a very 
effective barrier; as a result, only medications whose 
molecules are small enough to penetrate the skin can 
be delivered in this method. 
Oxybutynin (OXB) is a tertiary amine that has 
anticholinergic and direct spasmolytic effects on the 
bladder smooth muscle. It is widely used in the 
treatment of various forms of urinary incontinence 
and overactive bladder. Particularly, Oxybutynin 
(OXB) effectively treats neurologically caused 
bladder disorders.  
 
 
 
Fig 1: structural formula of oxybutynin 
However, after oral administration of Oxybutynin 
(OXB), many patients discontinue its use because of 
unacceptable anticholinergic side effects such as dry 
mouth, dizziness, blurred vision, and constipation. In 
some cases, the adverse side effects are severe 
enough to persuade the patient to discontinue 
treatment.(2)These side effects have been associated 
with the presence of active metabolite of Oxybutynin, 
N-desethyloxybutynin (N-DEO),which circulates in 
concentrations approximately 4 to 10 times those of 
the parent compound. Presystemic metabolism of 
Oxybutynin (OXB) occurs primary because of 
extensive hepatic first-pass metabolism with a small 
contribution by intraluminal gastrointestinal 
metabolism, resulting in oral bioavailability of 
approximately 6% of the oral dose.(3)To reduce or 
even eliminate systemic anticholinergic adverse 
effects of Oxybutynin, novel anticholinergic agents 
and dosage forms have been currently developed that 
may avoid the hepatic first-pass metabolism so they 
exhibit the pharmacological effects. In fact, it has 
been shown that transdermal adhesive matrix patches 
of Oxybutynin (OXB) avoids that extensive 
presystemic metabolism, and directly introduces the 
drug into blood stream, and consequently enhances 
the bioavailability.(4) However, the skin irritation 
caused by the transdermal adhesive matrix patches 
remain to be a problem. Sometimes the irritation may 
discourage patients to discontinue the treatment, 
particularly for the long-term users.(5)Thus, the 
needs still remain for the improved formulations of 
Oxybutynin (OXB), which may significantly reduce 
the adverse side effects and skin irritation. 
Therefore, in the present study, 
Transdermal patches were prepared according to the 
formula shown in Table 08. Eudragit L100, Eudragit 
S100 were weighed in requisite ratios and they 
were then dissolved in dimethyl formamide and 
ethanol as solvent using magnetic stirrer. Oxybutynin 
(100mg) with a magnetic stirrer. Propylene glycol 
and PEG 400 was added to the above dispersion  
under  continuous stirring. The uniform dispersion 
was poured in the petri plate. The rate of evaporation 
of solvent was controlled by inverting cut funnel over 
the patches. After 24h, the dried films were 
taken out and stored in desiccator.  
 
EXPERIMENTAL METHOD: 
Materials  
Oxybutynin, Eudragit L-100, Eudragit-S100, 
Dimethyl formamide, Ethanol, Propylene glycol all 
the chemicals used were lab grade 
 
Solvent casting method : Transdermal patches were 
prepared according to the formula shown in Table 
08. Eudragit L100, Eudragit S100 were weighed in 
requisite ratios and they 
were then dissolved in dimethyl formamide and 
ethanol as solvent using magnetic stirrer. Oxybutynin 
(100mg) with a magnetic stirrer. Propylene glycol 
and PEG 400 was added to the above dispersion  
under  continuous stirring. The uniform dispersion 
was poured in the petri plate. The rate of evaporation 
of solvent was controlled by inverting cut funnel over 
the patches. After 24h, the dried films were 
taken out and stored in desiccator.  
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Table 1: Formulations of Oxybutynin Transdermal Patch 
 
 
S.No 
 
Ingredients 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
1 Drug(mg) 100 100 100 100 100 100 100 100 100 
2 Eudragit-L100(mg) 100 200 300 400     200 
3 Eudragit-S100(mg)     100 200 300 400 200 
4 Dimethyl formamide (ml) 15 15 15 15 15 15 15 15 15 
5 Ethanol(ml) 10 10 10 10 10 10 10 10 10 
6 Propylene glycol(Drops) 5 5 5 5 5 5 5 5 5 
7 PEG 400(Drops) 20 20 20 20 20 20 20 20  
 
Physical appearance, Thickness, Weight variation, Flatness, Folding endurance, Moisture uptake, Moisture content, 
Drug content determination, In vitro permeation studies using dialysis membrane are the evaluation tests performed 
for the prepared patches. 
RESULTS AND DISCUSSION: 
Table 2: Standard graph of Oxybutynin 
 
Concentration (µg/ml) Absorbance 
0 0 
2 0.295 
4 0.203 
6 0.301 
8 0.417 
10 0.528 
12 0.653 
14 0.771 
16 0.881 
 
 
 
 
Fig  1 :  Standard curve of Oxybutynin 
Evaluation of Pioglitazone HCl Transdermal patches : 
Physical appearance : All the Transdermal patches were visually inspected for colour, clarity, flexibility. 
Flatness : All the Transdermal patches was found to be flat with out any foams. 
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Table 3 : Evaluation of Oxybutynin Transdermal patch by physical methods 
 
Formulation Weight 
variation (mg) 
Thickness 
(mm) 
Folding 
endurance 
Drug content 
(%) 
Moisture 
uptake (%) 
Moisture 
content (%) 
F1  
590.2 
 
0.569 
 
20 
 
65 
 
7.98 
 
3.77 
F2  
598.3 
 
0.520 
 
25 
 
65 
 
25.05 
 
9.2 
F3  
599.5 
 
0.570 
 
27 
 
57.5 
 
13.09 
 
5.16 
F4  
598.3 
 
0.596 
 
24 
 
60 
 
15.63 
 
5.66 
F5  
599.6 
 
0.560 
 
30 
 
67.5 
 
11.73 
 
4.87 
F6  
593.1 
 
0.517 
 
32 
 
92.5 
 
19.65 
 
12.67 
F7  
589.5 
 
0.578 
 
40 
 
99.7 
 
9.42 
 
3.43 
F8  
591.1 
 
0.537 
 
37 
 
85 
 
10.87 
 
4.72 
F9  
600 
 
0.503 
 
44 
 
100 
 
6.44 
 
3.62 
 
The prepared Oxybutynin Transdermal patches were evaluated for their physical parameters such as Physical 
appearance, Flatness, Weight variation, Thickness, Folding endurance, Drug content, Moisture uptake, Moisture 
content and all the results were found to be  were found to be within the pharmacoepial limits.  
 
Table 4:  Evaluation of Oxybutynin Transdermal patch by In-vitro permeation studies using dialysis 
membrane 
 
 
Time (Hrs) 
 
% Drug release 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
0 0 0 0 0 0 0 0 0 0 
0.5 2.31 2.98 2.36 2.06 2.10 1.11 4.43 2.59 5.86 
1 3.53 6.71 5.2 3.8 3.68 4.21 10.3 4.84 18.7 
2 6.78 11.9 12.7 7.48 8.50 8.01 19.8 10.3 40.9 
3 11.5 18 18.3 13.1 17.3 13.3 30.5 18.6 50.5 
4 15.7 2 24.4 16.5 19.0 18.4 46.4 21.1 61.0 
5 21.4 18.3 25.7 21.3 27.3 21.0 56.6 29.7 73.4 
6 27.5 20.6 29.6 26.6 35.0 35.1 67.6 34.3 83.1 
7 32.5 23.3 31.2 32.3 38.4 39.6 74.3 39.2 89.8 
8 37.6 25.8 34.1 35.8 42.8 44.8 84.1 43.9 99.6 
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Fig 2: %ge drug release of F1, F2, F3 
 
 
 
 
Fig 3: %ge drug release of F4, F5, F6 
 
 
 
 
Fig 4: %ge drug release of F7, F8, F9 
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The prepared Oxybutynin Transdermal patches were evaluated for In-vitro permeation studies using dialysis 
membrane, among all the 9 formulations F9 formulation was shown 99.6% cumulative drug release within 8 hours. 
 
Table 5: Kinetics of In-vitro permeation studies of optimized formulation  
 
Cumulative 
(%) release 
Q 
Time 
(T) 
Root 
(T) 
Log 
(%) 
release 
Log 
(T) 
Log 
(%) 
remain 
Release  
rate 
(cumulative 
% release/t) 
1/cum
% 
release 
Peppas    
log 
Q/100 
% 
drug 
remain 
Q01/3 Qt1/
3 
Q01/3-
Qt1/3 
0 
0 0 
  
2.000 
   
100 
 
4.642 
 
4.64
2 
 
0.000 
5.86 
0.5 
0.70
7 0.768 -0.301 1.974 11.720 0.1706 -1.232 94.14 
 
4.642 
 
4.54
9 
 
0.092 
18.7 
1 
1.00
0 1.272 0.000 1.910 18.700 0.0535 -0.728 81.3 
 
4.642 
 
4.33
2 
 
0.310 
40.9 
2 
1.41
4 1.612 0.301 1.772 20.450 0.0244 -0.388 59.2 
 
4.642 
 
3.89
5 
 
0.746 
50.5 
3 
1.73
2 1.703 0.477 1.695 16.833 0.0198 -0.297 49.5 
 
4.642 
 
3.67
2 
 
0.970 
61.0 
4 
2.00
0 1.785 0.602 1.591 15.250 0.0164 -0.215 39 
 
4.642 
 
3.39
1 
 
1.250 
73.4 
5 
2.23
6 1.866 0.699 1.425 14.680 0.0136 -0.134 26.6 
 
4.642 
 
2.98
5 
 
1.656 
83.1 
6 
2.44
9 1.920 0.778 1.228 13.850 0.0120 -0.080 16.9 
 
4.462 
 
2.56
6 
 
2.075 
89.8 
7 
2.64
6 1.953 0.845 1.009 12.829 0.0111 -0.047 10.2 
 
4.642 
 
2.16
9 
 
2.473 
99.6 
8 
2.82
8 1.998 0.903 -0.398 12.450 0.0100 -0.002 0.4 
 
4.642 
 
0.73
7 
 
3.905 
 
 
Fig 5: Zero order kinetics 
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Fig 6 : Higuchi plot  
 
 
 
Fig 7 : Peppas plot 
 
 
 
Fig 8 : First order kinetics 
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The kinetics of In-vitro permeation studies using 
dialysis membrane for F9 formulation was plotted 
and the F9 formulation followed the Higuchi 
mechanism of drug release. 
 
SUMMARY & CONCLUSION:  
In present study transdermal drug delivery of 
Oxybutynin was developed to overcome the first pass 
metabolism and to reduce frequency of dosing 
compared to oral route. Oral drug delivery system has 
various drawbacks like poor bioavailability due to 
hepatic metabolism (first pass) and the tendency to 
produce rapid blood level spikes (both high and low), 
leading to a need for high and/or frequent dosing, 
which can be both cost prohibitive and inconvenient. 
Matrix type of transdermal patches was developed by 
using polymers eudragit L100 and eudragit 
S100.Transdermal patches were prepared by 
employing solvent casting method. Propylene glycol 
and Tween80 were selected as permeation enhancer 
and plasticizer. Drug excipient compatibility studies 
were carried out by using FTIR, and it was observed 
that there were no interactions. Formulations were 
prepared with the varying concentrations polymers 
ranging from F1-F9, and all the formulations were 
evaluated for various physical parameters Physical 
appearance, Flatness, Weight variation, Thickness, 
Folding endurance, Drug content, Moisture uptake, 
Moisture content and Swelling study and all the 
results were found to be were found to be within the 
pharmacopeial limits, invitro drug release studies by 
using dialysis membrane. And f6 showed the better 
drug release. For F6 formulation release kinetics 
were plotted and the Regression coefficient value was 
found to be high for Korsmeyer-peppas release model 
i.e., 0.9892. The n value was found to be 0.6203 
which indicates the drug release pattern was found to 
be  non-Fickian diffusion. 
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